Luxbright (LXB) H1 2025 earnings summary

Executive summary

• Achieved over 60% year-over-year revenue growth to 5.4 MSEK, driven by sales of proprietary X-ray tubes and sources.

• Transitioned from a development-focused to a commercial company with global reach, expanding both product portfolio and strategic partnerships.

• Strengthened capital base through a rights issue, raising approximately 14 MSEK before costs.

• Initiated innovation projects in cold cathode technology and defense applications, including collaborations in South Korea and with Vinnova.

Financial highlights

• Net sales reached 5,385 KSEK (3,348 KSEK), a 61% increase year-over-year.

• Operating loss widened to -9,817 KSEK (-9,282 KSEK), with a negative operating margin.

• Net loss after tax was -9,972 KSEK (-9,287 KSEK), or -0.09 SEK per share (-0.10 SEK).

• Cash flow from operations was -11,243 KSEK (-7,905 KSEK); total cash flow for the period was 3,967 KSEK (-9,695 KSEK).

• Cash and cash equivalents at period end were 16,322 KSEK (4,344 KSEK).

Outlook and guidance

• No quantified forecast for 2025, but the company is considered well positioned for continued commercialization of its product series.